{"entity":{"id":"nct03075696","kind":"trial","name":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat","aka":[],"tldr":"A phase 1/2 trial of Glofitamab, Obinutuzumab, Tocilizumab in non-hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.","summary":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT03075696 by Hoffmann-La Roche, with 940 participants planned, started 2017-02-21 and due to reach its primary completion in 2029-03-30. Interventions recorded: Glofitamab, Obinutuzumab, Tocilizumab. Conditions listed: Non-Hodgkin's Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03075696","url":"https://clinicaltrials.gov/study/NCT03075696"}],"tags":["ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["glofitamab","obinutuzumab","tocilizumab"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03075696","phase":"1/2","setting":"A Multicenter, Open-label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma","sponsor":"Hoffmann-La Roche","enrolled":940,"outcomes":[]},"route":"/trials/nct03075696/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/"},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/"},{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}]}}